Stoke Therapeutics Reports Third Quarter 2026 Financial Results

Stoke Therapeutics reported third-quarter 2026 revenue of $11.3 million, exceeding the FactSet consensus estimate of $8.2 million. The company said it continues to advance its RNA-based medicine pipeline, including lead candidate zorevunersen, which is in late-stage clinical development for Dravet syndrome.